Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr;25(4):e716-e721.
doi: 10.1634/theoncologist.2019-0528. Epub 2019 Dec 19.

Single-Center Experience with Ifosfamide Monotherapy as Second-Line Treatment of Recurrent/Metastatic Osteosarcoma

Arie Jan Verschoor  1 , Frank M Speetjens  1 , P D Sander Dijkstra  2 , Marta Fiocco  3   4 , Michiel A J van de Sande  2 , Judith V M G Bovée  5 , Hans Gelderblom  1
Affiliations

Single-Center Experience with Ifosfamide Monotherapy as Second-Line Treatment of Recurrent/Metastatic Osteosarcoma

Arie Jan Verschoor et al. Oncologist. 2020 Apr.

Abstract

Background: The effectiveness of second-line palliative chemotherapy in patients with recurrent/metastatic osteosarcoma is not well defined. Several small studies (6-19 patients) have reported on ifosfamide as second-line treatment. In this study we report our single-center experience with second-line ifosfamide monotherapy in patients treated for recurrent/metastatic osteosarcoma.

Methods: A chart review was conducted of all patients with osteosarcoma treated with ifosfamide from 1978 until 2017. Until 1997 a 5 g/m2 regimen was used, and from 1997 onwards a 9 g/m2 regimen was used. Overall survival (OS) from start of ifosfamide was the primary endpoint. Progression-free survival (PFS) from start of treatment was also studied. To assess difference in survival between groups the log rank test was applied. To investigate the effect of ifosfamide dose and World Health Organization performance status (PS) a Cox proportional hazard regression model was estimated.

Results: Sixty-two patients were selected with recurrent/metastatic osteosarcoma treated with second-line ifosfamide monotherapy (dose of 5 g/m2 , n = 26; 9 g/m2 , n = 36). OS was significantly better in univariate analysis for 9 g/m2 compared with 5 g/m2 (10.9 months [95% confidence interval (CI), 9.3-12.6] vs. 6.7 months [95% CI, 5.9-7.6], respectively) and for PS (median OS PS 0, 13.0 months [95% CI, 2.3-23.8]; PS 1, 8.2 months [95% CI, 5.4-11.1]; PS ≥2, 6.2 months [95% CI, 2.2-10.3]; and unknown PS, 5.4 months [95% CI, 2.2-8.5]). In multivariate analysis only PS showed a significant difference. No difference in PFS was found between 5 and 9 g/m2 ifosfamide treatment or PS.

Conclusion: This study suggests that ifosfamide is an effective second-line treatment for patients with recurrent/metastatic osteosarcoma.

Implications for practice: Ifosfamide monotherapy is commonly used as second-line treatment in osteosarcoma, although large series to support this are lacking. This retrospective study reports overall and progression-free survival for regimens with 5 g/m2 and with 9 g/m2 . This study was unable to show a significant difference in survival between 5 and 9 g/m2 but showed an important impact of World Health Organization performance status on overall survival. This study sets a standard and reference for comparison with the multiple phase II studies under development.

Keywords: Chemotherapy; Ifosfamide; Metastasis; Osteosarcoma; Survival.

PubMed Disclaimer

Conflict of interest statement

Disclosures of potential conflicts of interest may be found at the end of this article.

Figures

Figure 1
Figure 1
Overall survival. (A): All patients. (B): Split based on dose. (C): Split based on WHO performance score.Abbreviation: WHO, World Health Organization.
Figure 2
Figure 2
Progression‐free survival. (A): All patients. (B): Split based on dose. (C): Split based on WHO performance score.Abbreviation: WHO, World Health Organization.
See this image and copyright information in PMC

References

    1. Bielack SS, Kempf‐Bielack B, Delling G et al. Prognostic factors in high‐grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776–790. - PubMed
    1. Meyers PA, Schwartz CL, Krailo MD et al.; Children's Oncology Group. Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival—A report from the Children's Oncology Group. J Clin Oncol 2008;26:633–638. - PubMed
    1. Smeland S, Bruland OS, Hjorth L et al. Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow‐up of 4 years. Acta Orthop 2011;82:211–216. - PMC - PubMed
    1. Lewis IJ, Nooij MA, Whelan J et al.; European Osteosarcoma Intergroup. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: A randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007;99:112–128. - PubMed
    1. Marina NM, Smeland S, Bielack SS et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high‐grade osteosarcoma (EURAMOS‐1): An open‐label, international, randomised controlled trial. Lancet Oncol 2016;17:1396–1408. - PMC - PubMed

MeSH terms